Regional adoptive immunotherapy with interleukin-2 and lymphokine-activated killer (LAK) cells for liver metastases.
A phase lb trial of a novel regional approach to adoptive immunotherapy is reported. Patients with liver metastases received continuous high-dose infusion of interleukin-2 (IL-2) into the splenic artery or intravenous infusion with subsequent transfer of lymphokine-activated killer (LAK) cells into the portal vein or the hepatic artery. Trafficking studies revealed homogeneous distribution of the LAK cells within the liver. The usual side-effects of IL-2 and LAK cells occurred without limiting liver toxicity. One partial (7+ months) and two complete responses (36 and 26+ months) were observed in 9 patients with metastases from cutaneous melanoma. None of 6 patients with metastases from ocular melanoma responded.
Keilholz
U
U
Department of Internal Medicine V, University of Heidelberg, Germany.
Scheibenbogen
C
C
Brado
M
M
Georgi
P
P
Maclachlan
D
D
Brado
B
B
Hunstein
W
W
D005134:Eye Neoplasms / Q000473:pathology; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000009:adverse effects / Q000379:methods*; D007376:Interleukin-2 / Q000627:therapeutic use*; D015979:Killer Cells, Lymphokine-Activated / Q000637:transplantation*; D007937:Leukapheresis; D008099:Liver / Q000276:immunology; D008113:Liver Neoplasms / Q000556:secondary* / Q000628:therapy*; D008545:Melanoma / Q000473:pathology*; D012878:Skin Neoplasms / Q000473:pathology
D007376:Interleukin-2